echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Phase 2 clinical results of innovative tau protein vaccine for the treatment of Alzheimer's disease published

    Phase 2 clinical results of innovative tau protein vaccine for the treatment of Alzheimer's disease published

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Axon Neuroscience announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-published Nature Aging


    In AD patients confirmed by disease biomarkers, AADvac1 showed efficacy signals, which significantly delayed the decline of clinical and functional indicators in patients


    Neurofibrillary tangles (NFT) composed of pathological tau protein aggregation is one of the hallmarks of AD patients’ brains


    AADvac1 is a tau protein vaccine designed to target the production and spread of pathological tau protein


    In a 24-month randomized double-blind, placebo-controlled phase 2 clinical trial, AADvac1 reached the primary endpoint of the trial, showing good safety and tolerability


    In addition, AADvac1 significantly reduced the accumulation of nerve fiber light chain (NfL)


    In the subgroup of AD patients confirmed by AD biomarker amyloid deposition and tau protein aggregation, compared with placebo, AADvac1 delayed the clinical decline detected by CDR-SB by 27% (p=0.


    Note: The original text has been deleted

    Reference materials:

    Reference materials:

    [1] Nature Aging publishes phase II results for AADvac1, a first-in-man Alzheimer's tau vaccine developed by Axon Neuroscience.


    [1] Nature Aging publishes phase II results for AADvac1, a first-in-man Alzheimer's tau vaccine developed by Axon Neuroscience.


    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.